Relmada Therapeutics (RLMD) Change in Acquisitions & Divestments (2020 - 2026)

Relmada Therapeutics (RLMD) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $14.3 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $14.3 million, down 9.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.1 million (down 45.31% YoY), and the FY2025 annual result was $35.7 million, down 43.92% from the prior year.
• Change in Acquisitions & Divestments grew to $14.3 million in Q1 2026 per RLMD's latest filing, from $5.9 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $74.8 million in Q1 2023 and troughed at $5.9 million in Q4 2025.
• A 5-year average of $18.9 million and a median of $15.3 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments plunged 86.53% in 2022, then jumped 517.79% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $6.6 million in 2022, then jumped by 517.79% to $41.1 million in 2023, then slumped by 70.77% to $12.0 million in 2024, then tumbled by 51.2% to $5.9 million in 2025, then surged by 144.04% to $14.3 million in 2026.
• Business Quant data shows RLMD's Change in Acquisitions & Divestments at $14.3 million in Q1 2026, $5.9 million in Q4 2025, and $7.0 million in Q3 2025.